StocksDiva Bio Bin

[StocksDiva]

ADXS Advaxis' HER2 immunotherapy candidate receives Orphan Drug Designation for treatment of osteosarcoma (ADXS) :

Co announced that it has been granted Orphan Drug Designation (:ODD) from the FDA Office of Orphan Products Development for ADXS-cHER2 for the treatment of osteosarcoma.
"Looking ahead, Advaxis is now planning to initiate a clinical development program in pediatric osteosarcoma with ADXS-cHER2. Given the limited availability of new treatment options for pediatric osteosarcoma, we believe that, subject to regulatory approval and upon completion of successful clinical trials, the potential to be on the market may be accelerated."